Cargando…
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 mill...
Autores principales: | Ustianowski, Andrew, Arends, Joop E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471058/ https://www.ncbi.nlm.nih.gov/pubmed/26032649 http://dx.doi.org/10.1007/s40121-015-0070-1 |
Ejemplares similares
-
Twenty years of childhood blindness: what have we learnt?
por: Gilbert, Clare, et al.
Publicado: (2008) -
10 Years of belimumab experience: What have we
learnt?
por: Levy, Roger A, et al.
Publicado: (2021) -
Defining transposition: What have we learnt?
por: Roderick, Max E., et al.
Publicado: (2021) -
What have we learnt from Covid?
por: Salter, Mark Steven
Publicado: (2021) -
What have we learnt from the EMC effect?
por: Pirner, H J
Publicado: (1986)